A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs BNC 210 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Bionomics
- 16 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Treatment arms has been increases from 2 to 4 and patients number also increases.
- 11 Apr 2017 Planned number of patients changed from 160 to 192.